Allergy

This analysis of the phase 3 LIBERTY ASTHMA QUEST study analyzed data for patients with and without allergic rhinitis.

Investigators found that age, gender, and allergy test setting were not significantly associated with penicillin allergy label persistence.

How do current peanut allergy immunotherapies compare, and what other allergens may be addressed next?

Investigative therapy PVX108 showed a favorable tolerability and safety profile in patients with peanut allergies.

How did dupilumab fare in patients with chronic rhinosinusitis with nasal polyps?

Having asthma was associated with sensitization to 1 or more allergens. Having sensitization to the individual allergens—mouse, cockroach, and dust mite—were also associated with sensitization to 1 or more allergens.

Why both physicians and patients need to be on the same page when considering food allergy oral immunotherapy.

Why peanut allergy therapies are prioritized in early trials, and how far out are complimentary therapies to the ones currently being investigated.

Investigators hope the results will increase public support for prescribed fires that help maintain forest health and prevent wildfires.

A group of pediatric patients were able to sustain desensitization 4 weeks after stopping the daily oral immunotherapy.

How far in advances of care have we come, what issues are most pressing in the field now, and what specialties with be involved in future meetings?

The introduction of biologics such as dupilumab have opened avenues of care for patients with overlapping disease.

The biologic's indications for inflammatory diseases are greatly varied and still developing, and it owes some of that to recent advances in disease prognosis.

The AAAAI 2019 president explains why research is already dedicated toward improving investigative peanut allergens.

The Regeneron VP explains how dupilumab could possibly serve as a complimentary therapy to Aimmune's investigative food allergy therapy.

Results showed a statistically significant difference in responder rate between active treatment and placebo but didn’t meet a prespecified threshold for clinical significance.

The Program Chair explains how the meeting has improved over 3 decades, and highlights his favorite sessions to come at the 2019 meeting.

The intranasal epinephrine spray is being developed for use with Intravail, a nasal absorption enhancing technology.

The EPIT skin patch is still seeking indication as the first peanut allergy desensitization therapy to reach the market.

A new survey study found that less than half of food allergies reported by adults have actually been diagnosed by a physician.

Children often develop food allergies prior to developing asthma, and the former condition is associated with a greater risk of the latter condition in later life.